<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468012</url>
  </required_header>
  <id_info>
    <org_study_id>#6022</org_study_id>
    <secondary_id>6022</secondary_id>
    <nct_id>NCT01468012</nct_id>
  </id_info>
  <brief_title>Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence</brief_title>
  <acronym>COST</acronym>
  <official_title>Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will look at cocaine dependent individuals and will consist of three
      consecutive phases: 1) the 2-week outpatient lead-in phase during which behavioral therapy
      will be administered; 2) the 15-21 day inpatient phase (during which participants will start
      study medication of levodopa,carbidopa and entacapone (LCE) and will undergo brain imaging
      and 3) the 24 weeks outpatient treatment trial. The purpose is to see if treatment with LCE
      may reverse baseline brain deficits and if this change is associated with clinical
      improvement. Hypothesis is that treatment with LCE, compared to placebo, increases abstinence
      from cocaine over a 12-week trial in combination with behavioral treatment with voucher
      incentives.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine dependence remains a serious public health problem; however no clearly effective
      pharmacological treatments have been identified to date. The investigators hypothesize that
      identification of subgroups of cocaine-dependent patients will help to develop targeted and
      more effective treatments. The investigators have observed that 30-40% of cocaine-dependent
      patients who enter our medication trials achieve abstinence during the lead-in period (the
      two weeks prior to starting medication). Initial abstinence is strongly predictive of
      abstinence during the subsequent medication trial. The investigators have also observed that
      a low dopamine release in the striatum is associated with greater choice of cocaine in
      volunteers and failure of cocaine-dependent patients to respond to behavioral treatment. The
      investigators hypothesize that individuals who have difficulties in achieving abstinence have
      a deficit in dopaminergic functioning and correcting this deficit using dopaminergic
      medication LCE (levodopa in combination with carbidopa and entacapone) will result in
      clinical improvement.

      The proposed study will consist of three consecutive phases: 1) the 2-week outpatient lead-in
      phase during which behavioral therapy will be administered; 2) the 15-21 day inpatient phase
      (during which participants will start study medication and will undergo brain imaging; one
      PET and two fMRI scan sessions); and 3) the 24 weeks outpatient treatment trial.

      Study medication (LCE or placebo) will be administered in a double-blind, placebo controlled
      manner for one week during inpatient phase followed by 12 weeks of the outpatient trial.
      During the remaining 12 weeks of the outpatient trial participants will receive therapy only.

      The purpose of the lead-in phase is to identify patients who do not achieve abstinence in
      response to behavioral treatment. Subsequently, two matched subgroups of participants (half
      who achieved abstinence and half who did not achieve abstinence) will undergo the [11C]
      raclopride displacement PET brain imaging procedure. This procedure allows the measurement of
      dopamine release in response to a single dose of methylphenidate, and the investigators will
      determine if failure to achieve abstinence during the lead-in period is associated low
      dopamine transmission.

      All participants in the proposed study will also undergo a functional MRI with the
      Motivational Incentive Delay task (fMRI/MID). This task is thought to reflect dopaminergic
      transmission in the brain-reward system but is safer and more feasible than PET. The
      investigators hypothesize that fMRI/MID will correlate strongly with results from the PET
      procedure, thereby suggesting that it also reflects the status of striatal dopamine
      functioning. In addition, a group of healthy controls will undergo one fMRI scan in order to
      validate the procedure and to assess if a deficit can be detected in cocaine-dependent
      participants. Cocaine-dependent participants will undergo two fMRI/MID, one at baseline and
      another after a week of treatment with LCE to assess if treatment with LCE may reverse
      baseline deficits and if this change is associated with clinical improvement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Urine Toxicology</measure>
    <time_frame>collected 3x/week for 24 weeks of trial or for the duration of the participants involvement in the study.</time_frame>
    <description>Abstinence will be assessed by urine toxicology results collected 3x/week during the 24 week trial or for the length of participation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention in Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of participants who completed the 12-week medication phase of the study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>levodopa carbidopa and entacapone (LCE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa carbidopa and entacapone (LCE)</intervention_name>
    <description>400mg/100mg/200mg, twice daily</description>
    <arm_group_label>levodopa carbidopa and entacapone (LCE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo for LCE condition dosed twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult, age 21-50.

          -  Meets DSM-IV criteria for current cocaine dependence, supported by a positive urine
             for cocaine metabolites

          -  Voluntarily seeking treatment for cocaine dependence

          -  Absence of other medical or psychiatric disorders that are unstable and would
             interfere with participation.

          -  Absence of any suspicious skin changes, suggestive of melanoma, during the full body
             exam

          -  Able to give informed consent.

        Exclusion Criteria:

          -  Current DSM-IV criteria of other substance use disorders with the exception of
             nicotine dependence, and mild to moderate alcohol or cannabis abuse or dependence.
             Alcohol or cannabis abuse or dependence may be included provided that cocaine is the
             predominant problem, and medical detoxification is not indicated; alcohol and cannabis
             use are common among cocaine dependent patients and their categorical exclusion would
             impede recruitment and result in a sample of limited generalizability; secondary
             analyses will explore whether they exert any moderating effects on the main findings.

          -  Active psychiatric disorder which might interfere with participation or make
             participation hazardous, including DSM-IV organic mental disorder, psychotic disorder,
             bipolar disorder, recurrent severe MDD, OCD, or eating disorder. Participants with
             depressive disorder (provided that the score on the Hamilton Depression Scale is less
             than 20) and those with ADHD symptoms may be included, since these are common, often
             reflect effects of chronic drug use, and may improve with behavioral treatment and
             cessation or reduction of drug use.

          -  Unstable medical disorders, or medical disorders that might interfere with study
             participation, including seizure disorder.

          -  Significant current suicidal risk or 1 or more suicide attempts within the past year

          -  Concurrent treatment with psychotropic medications

          -  Positive serum pregnancy test, lactation, or unwillingness to use a satisfactory
             method of birth control

          -  Baseline systolic BP of &gt; 140 and &lt; 100, diastolic BP &gt; 90 and &lt; 60 and baseline HR
             greater than 90.

          -  Any clinically significant heart abnormality or cardiovascular disease

          -  History of glaucoma

          -  History of melanoma or current suspicious undiagnosed skin lesions

          -  History of allergic reaction or adverse reaction to study medications
             (levodopa/carbidopa/entacapone; methylphenidate; raclopride).

          -  Metal implants or paramagnetic objects contained within the body which may interfere
             with the MRI scan as determined in consultation with a neuroradiologist and according
             to the guidelines set forth in the following reference book commonly used by
             neuroradiologists: &quot;Guide to MR procedures and metallic objects&quot; by Shellock

          -  Lifetime exposure to radiation in the workplace, or history of participation in
             nuclear medicine procedures, including research protocols

          -  Individuals who are predominantly left handed. Based on a score &lt;50 on the Edinburg
             Handed Inventory (E.H.I.).

        Inclusion Criteria(fMRI study-healthy controls):

          -  Adult, age 21-50.

          -  No current DSM-IV psychiatric or substance use disorders

          -  Absence of other medical disorders that are unstable and would interfere with
             participation.

          -  Able to give informed consent.

        Exclusion Criteria (fMRI study-healthy controls):

          -  Current or recent DSM-IV psychiatric or substance use disorders

          -  Past history of any major Axis I disorder (e.g., psychotic disorders, bipolar
             disorder, recurrent major depressive disorder, OCD or eating disorders).

          -  Unstable medical disorders, or medical disorders that might interfere with study
             participation.

          -  Concurrent treatment with psychotropic medications

          -  Positive serum pregnancy test, lactation, or unwillingness to use a satisfactory
             method of birth control *

          -  Baseline systolic BP of &gt; 140 and &lt; 100, diastolic BP &gt; 90 and &lt; 60 and baseline HR
             greater than 90.

          -  Any clinically significant heart abnormality or cardiovascular disease

          -  History of allergic reaction or adverse reaction to study medications
             (methylphenidate; raclopride).

          -  Metal implants or paramagnetic objects contained within the body which may interfere
             with the MRI scan as determined in consultation with a neuroradiologist and according
             to the guidelines set forth in the following reference book commonly used by
             neuroradiologists: &quot;Guide to MR procedures and metallic objects&quot; by Shellock

          -  Individuals who are predominantly left handed. Based on a score &lt;50 on the Edinburg
             Handed Inventory (E.H.I.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Bisaga, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>STARS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>October 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2016</results_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Adam Bisaga</investigator_full_name>
    <investigator_title>Research Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>cocaine dependence</keyword>
  <keyword>levodopa</keyword>
  <keyword>carbidopa</keyword>
  <keyword>entacapone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Entacapone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Levodopa Carbidopa and Entacapone (LCE)</title>
          <description>400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
levodopa carbidopa and entacapone (LCE): 400mg/100mg/200mg, twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo
Placebo: matched placebo for LCE condition dosed twice daily</description>
        </group>
        <group group_id="P3">
          <title>Non-randomized</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levodopa Carbidopa and Entacapone (LCE)</title>
          <description>400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
levodopa carbidopa and entacapone (LCE): 400mg/100mg/200mg, twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo
Placebo: matched placebo for LCE condition dosed twice daily</description>
        </group>
        <group group_id="B3">
          <title>Non-randomized</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Urine Toxicology</title>
        <description>Abstinence will be assessed by urine toxicology results collected 3x/week during the 24 week trial or for the length of participation</description>
        <time_frame>collected 3x/week for 24 weeks of trial or for the duration of the participants involvement in the study.</time_frame>
        <population>Urine toxicology results were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Levodopa Carbidopa and Entacapone (LCE)</title>
            <description>400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
levodopa carbidopa and entacapone (LCE): 400mg/100mg/200mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Placebo: matched placebo for LCE condition dosed twice daily</description>
          </group>
          <group group_id="O3">
            <title>Non-randomized</title>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Urine Toxicology</title>
          <description>Abstinence will be assessed by urine toxicology results collected 3x/week during the 24 week trial or for the length of participation</description>
          <population>Urine toxicology results were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Retention in Treatment</title>
        <description>The number of participants who completed the 12-week medication phase of the study.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa Carbidopa and Entacapone (LCE)</title>
            <description>400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
levodopa carbidopa and entacapone (LCE): 400mg/100mg/200mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Placebo: matched placebo for LCE condition dosed twice daily</description>
          </group>
          <group group_id="O3">
            <title>Non-randomized</title>
            <description>Participants who dropped from the study prior to randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Retention in Treatment</title>
          <description>The number of participants who completed the 12-week medication phase of the study.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Levodopa Carbidopa and Entacapone (LCE)</title>
          <description>400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
levodopa carbidopa and entacapone (LCE): 400mg/100mg/200mg, twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo
Placebo: matched placebo for LCE condition dosed twice daily</description>
        </group>
        <group group_id="E3">
          <title>Non-randomized</title>
          <description>Participants who dropped from the study prior to randomization</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for shortness of breath</sub_title>
                <description>It was determined that the participant had a presence of Sinus of Valsalva aneurysm on Aortic Valve.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hospitalization for chest pain</sub_title>
                <description>It was determined that the participant had a presence of Sinus of Valsalva aneurysm on Aortic Valve.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for leg numbness</sub_title>
                <description>The participant was hospitalized for numbness and pain in the left leg which occurred in the non-medication follow-up phase of the study. The participant was diagnosed with Multiple Sclerosis during the hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hospitalization for Leg pain</sub_title>
                <description>The participant was hospitalized for numbness and pain in the left leg which occurred in the non-medication follow-up phase of the study. The participant was diagnosed with Multiple Sclerosis during the hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular Heart rate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>GI Upset</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>increased libido</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Prolonged Erection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Bisaga</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-6155</phone>
      <email>bisagaa@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

